Caduet

Pro-RU486 `Taking a pill is like taking an aspirin, much more natural.With this I spend two or three hours and now I'm going to work. There were no problems. It's very simple.'.

Cabergoline .48 CADUET .31, 33 calcitonin salmon injectable.45 Calcium Channel Blocking Agents .31 Calcium Channel Modifying Agents .7 CAMPRAL .40 CAMPTOSAR .18 CANASA .52 CANTIL .41 CAPASTAT.15 CAPEX.44 CAPITROL.39 captopril hctz .34 captoprill.34 carbachol .54 carbamazepine .7 CARBATROL .7 carbidopa and levodopa.20 carbidopa and levodopa cr.20 CARDIOQUIN .29 CARDIOVASCULAR AGENTS .29 CARDIZEM LA.30, 31 carisoprodol.60 carteolol .55 CARTROL.24, 31 CATAPRES TTS .25 Catechol O-methyltransferase COMT ; Inhibitors .20 CAVERJECT .43, 46.
Ere's some news to chew on: A healthy mouth helps make a healthy body. Caring for your teeth and gums helps freshen your breath and stops tooth decay. But a healthy mouth also helps guard against gum disease. And that's important. People with gum disease may be more likely to have: s Heart problems. s A stroke. s Lung problems. s Diabetes. And pregnant women with gum disease could have a baby that is born too soon and too small. Mouth care tips s Brush your teeth and gums daily. Pick a toothbrush with soft. BIAXIN XL, 8 bicalutamide, 11 BIDIL, 15 bimatoprost, 36 bisoprolol, 14 bisoprolol hydrochlorothiazide, 14 BLEPH-10, 35 BLEPHAMIDE SOP, 35 bosentan, 15 BRAVELLE, 23 BRETHINE, 31 BREVICON, 22 brimonidine 0.1%, 0.15%, 36 brimonidine 0.2%, 36 brinzolamide, 35 bromocriptine, 17 brompheniramine pseudoephedrine 4 mg 45 mg per 5 mL, 30 brompheniramine pseudoephedrine ext-rel 12 mg 120 mg, 30 brompheniramine pseudoephedrine ext-rel 6 mg 60 mg, 30 budesonide, 25, 31 budesonide spray, 31 budesonide formoterol, 31 bumetanide, 15 BUMEX, 15 bupropion, 17 bupropion ext-rel, 17, 19 BUSPAR, 16 buspirone, 16 busulfan, 11 butalbital acetaminophen caffeine, 7 butalbital aspirin caffeine, 7 butenafine, 32 BYETTA, 20 cabergoline, 24 CADUET, 14 CAFERGOT, 18 CALAN, 14 CALAN SR, 14 calcipotriene, 32 calcitonin-salmon, 21 calcitriol 1, 25-D3 ; , 29 calcium acetate, 24 CAMPRAL, 19 CANASA, 25 candesartan, 13 candesartan hydrochlorothiazide, 13 capecitabine, 11 CAPOTEN, 12 CAPOZIDE, 12 captopril, 12 captopril hydrochlorothiazide, 12 CARAC, 32 CARAFATE, 26 carbamazepine, 16 carbamazepine ext-rel, 16 CARBATROL, 16 carbidopa levodopa, 17 carbidopa levodopa ext-rel, 17 carbidopa levodopa entacapone, 17. Estrictions related to artificial and natural nails will go into effect on November 1 for all staff who provide "hands-on" direct patient care. GBMC's Infection Control Committee has endorsed the Center for Disease Control's 2002 Guideline for Hand Hygiene in Healthcare Settings and has issued the following policy: Artificial fingernail enhancements contribute to nail changes that can increase the risk of colonization and transmission of pathogens to patients and therefore are forbidden.

Caduet sale This new catheter is expected to allow doctors to more comfortably treat men who suffer from the symptoms of bph , a condition that affects 23 million men and ascorbic. He following questions about selected Patient Safety Advisory articles may be useful for internal education and assessment. You may use the following examples or come up with your own. The Patient Safety Authority works with the Pennsylvania Medical Society to offer AMA PRA Category 1 CreditsTM for selected portions of the Patient Safety Advisory through the online publication Studies in Patient Safety: Online CME Cases. Go to : pamedsoc studies to find out more about patient safety CME opportunities. If the cost of your thyroid medicine is a concern for you, talk with your doctor about using a generic product and chlorthalidone, for example, lisinopril.

Caduet ingredients LIPITOR 4.8.2.1 HMG-COA COMBINATIONS $$$$ ADVICOR $$$$ VYTORIN $$$$$ CADUET 4.9 OTHER CARDIOVASCULAR DRUGS $ pentoxifylline * 5.1.1 ANALGESICS $ tramadol hcl * $ tramadol hcl-acetaminophen 5.1.1.1 CLASS II NARCOTICS $ fentanyl * $ hydromorphone hcl. Allergies anti-depressants anti-infectives anti-psychotics anti-smoking antibiotics asthma cancer cardio & blood cholesterol diabetes epilepsy gastrointestinal hair loss herpes hiv hormonal men's health muscle relaxers other pain relief parkinson's rheumatic skin care weight loss women's health allegra atarax benadryl clarinex claritin clemastine periactin phenergan pheniramine zyrtec anafranil celexa cymbalta desyrel effexor elavil, endep luvox moclobemide pamelor paxil prozac reboxetine remeron sinequan tofranil wellbutrin zoloft albenza amantadine aralen flagyl grisactin isoniazid myambutol pyrazinamide sporanox tinidazole vermox abilify clozaril compazine flupenthixol geodon haldol lamictal lithobid loxitane mellaril risperdal seroquel nicotine zyban achromycin augmentin bactrim biaxin ceclor cefepime ceftin chloromycetin cipro, ciloxan cleocin duricef floxin, ocuflox gatifloxacin ilosone keftab levaquin minomycin noroxin omnicef omnipen-n oxytetracycline rifater rulide suprax tegopen trimox vantin vibramycin zithromax advair aerolate, theo-24 brethine, bricanyl ketotifen metaproterenol proventil, ventolin serevent singulair arimidex casodex decadron eulexin femara levothroid, synthroid nolvadex provera, cycrin ultram vepesid zofran acenocoumarol aceon adalat, procardia altace atenolol amlodipine avapro caduet calan, isoptin capoten captopril hctz cardizem cardura catapres cilexetil, atacand clonidine, hctz combipres cordarone coreg coumadin cozaar dibenzyline diovan fosinopril hydrochlorothiazide hytrin hyzaar inderal ismo, imdur isordil, sorbitrate lanoxin lasix lercanidipine lopressor lotensin lozol micardis minipress moduretic normadate norpace norvasc plavix plendil prinivil, zestril prinzide rythmol tenoretic tenormin trental valsartan hctz vaseretic vasodilan vasotec zebeta crestor lipitor lopid mevacor pravachol tricor zocor accupril actos alpha-lipoic acid amaryl avandia diamicron mr gliclazide metformin glucophage glucotrol glucotrol xl glucovance lyrica micronase orinase prandin precose starlix depakote dilantin lamictal neurontin sodium valproate tegretol topamax trileptal valparin aciphex asacol bentyl cinnarizine colospa compazine cromolyn sodium cytotec imodium motilium nexium nexium fast pepcid ac pepcid complete prevacid prilosec propulsid protonix reglan stugil zantac zelnorm zofran propecia, proscar famvir rebetol valtrex zovirax combivir duovir-n epivir pyrazinamide retrovir sustiva videx viramune zerit ziagen aldactone calciferol danocrine decadron prednisone provera, cycrin synthroid avodart flomax hytrin levitra propecia, proscar viagra lioresal soma tizanidine ibuprofen zanaflex accupril alpha-lipoic acid amantadine aralen arcalion aricept ascorbic acid benadryl bentyl betahistine calciferol carbimazole compazine cyklokapron ddavp, stimate detrol dihydroergotoxine ditropan dramamine exelon florinef imitrex imuran isoniazid lasix melatonin myambutol nimotop orap persantine piracetam pletal quinine rifampin rifater rocaltrol strattera ticlid tiotropium urecholine urispas urso vermox zyloprim acetylsalicylic acid advil, medipren celebrex flunarizine imitrex ketorolac maxalt ponstel tylenol ultram benadryl ditropan eldepryl requip sinemet trivastal advil, medipren arava colchicine decadron feldene indocin sr mobic naprelan naprosyn zyloprim betamethasone differin nizoral oxsoralen prograf retin-a xenical advil, medipren allyloestrenol clomid, serophene diflucan evista folic acid fosamax isoflavone nexium parlodel ponstel prevacid prilosec progesterone provera, cycrin rocaltrol tibolone generic brethine, bricanyl generic name: terbutaline sulphate ; qty and tenoretic. Drug Name bumetanide injection bumetanide oral BUMEX INJECTION BUMEX ORAL CADUET ORAL CALAN ORAL CALAN SR ORAL CAPOTEN ORAL CAPOZIDE ORAL captopril & hydrochlorothiazide oral captopril oral CARDENE I.V. INTRAVENOUS CARDENE ORAL CARDENE SR ORAL CARDIZEM CD ORAL CARDIZEM INTRAVENOUS CARDIZEM LA ORAL CARDIZEM ORAL CARDIZEM SR ORAL CARDURA ORAL CARTROL ORAL CATAPRES ORAL CATAPRES-TTS 2 TRANSDERMAL CATAPRES-TTS-1 TRANSDERMAL CATAPRES-TTS-2 TRANSDERMAL CATAPRES-TTS-3 TRANSDERMAL chlorothiazide oral chlorthalidone oral CHLORTHALIDONE ORAL TABS 100MG cholestyramine light oral pack Drug Tier on Drug Tier on 2 TIER Benefit 3 TIER Benefit A 1 A Limited to 1 per week PA QL Limited to 1 per week GP GP GP GP, PA PA GP GP, PA GP PA GP Requirements Limits PA.

This paper is focused on distributed renewable energy technologies renewables ; . There are several renewable energy technologies that do not fit into this class, and are thus not considered in this paper. Net metering is one of several mechanisms that can be introduced to support the development of distributed renewables. It is a relatively straightforward approach that utilities could undertake to support renewables, as the majority of the effort for purchasing and utilizing renewables is on the part of the customer-generators. An alternative approach to promote distributed renewables would be through utility programs which install and maintain technologies at customer premises, similar to the SMUD PV Pioneers I program where residential customers pay US per month for 10 years to have a utility-owned solar PV system installed at their house76. Currently in British Columbia, there is neither a net metering program nor a utility-driven program to facilitate the interconnection of distributed renewables, with the exception of the BCIT solar PV demonstration site. Overall, there is no market in British Columbia associated with distributed renewables for grid intertied applications because of the lack of such programs. The West Kootenay Power green rate has, to date, only focused on large-scale wind energy technologies and may focus on non-distributed hydroelectricity. If policymakers are interested in promoting distributed renewables for grid applications, either a net metering rate or a utility program will need to be introduced. Otherwise, the distributed renewables market will remain stagnant as it currently is for grid applications. This paper does not take a position that net metering is superior to utility driven mechanisms because there has been no effort here to study those possibilities, nor to assess the disadvantages of net metering relative to those mechanisms. However, there are several considerations outlined below which could be used to build a case for net metering. They are broadly focused on: 1 ; the merits of the private-sector focus of net metering; 2 ; that utility benefits for each distributed renewable installation are small relative to other options, but the customer-generator benefits are potentially significant; and 3 ; that the installation and maintenance of distributed renewables is best undertaken at a grass-roots level rather than by utility personnel. Net metering is a private-sector, consumer-based mechanism. Currently, an extensive consumer market is established for renewable energy technologies for remote power applications. In British Columbia alone, there are already a number of profitable full service companies that offer renewable energy products and services for remote and mobile power applications.77 They advertise through their communities, through the Internet, in the yellow-pages under Solar Energy, in trade journals78, and at tradeshows. These companies have established distribution and atomoxetine. For All Programs All compounded prescription claims must be submitted on-line electronically. This is a mandatory requirement and no paper submissions for compounds will be processed. Only 25 ingredients are allowed for a compound claim transmitted on-line. Compounds having more than 25 ingredients should first be submitted on-line for 25 ingredients and then submitted on Form 3700 for the remaining ingredients. Submittal of Form 3700 must be made within 9 days of the processing of the original claim to the appropriate Regional Pharmacist. A compound claim must contain 2 or more ingredients. Only one compound claim is allowed per transmission and cannot be included in a multiple claim transaction. The Product ID NDC ; field 47-D7 ; in the required Claim Segment must contain all zeros. See Attachment 2 for the Billing Transaction `Compound Claim Segment'.

National medical laboratory professionals week coming soon, for instance, pregnancy. The headache grew worse and aku became extremely irritable and imuran. Wholesaling a drug premix; importing or compounding, pursuant to a prescription, a drug that is not commercially available in Canada by one of the following persons, namely, i ; a pharmacist, ii ; a practitioner, and iii ; a person who compounds a drug under the supervision of a practioner; any activity with respect to a drug that is used only for the purposes of clinical testing in accordance with subsection C.05.006 1 ; or section C.08.005; fabricating, packaging labelling, testing as required under Division 2, distributing as a distributer referred to in section C.01A.003, wholesaling or importing any of the following drugs for which prescriptions are not required and that are for human use in dosage form and not represented as a treatment, preventative or cure for any of the diseases, disorders or abnormal physical states set out in Schedule A to the Act, namely, i ; homeopathic drugs, ii ; drugs that meet the requirements of a class monograph entitled "Vitamin Supplements", "Mineral Supplements", "Dietary Vitamin Supplements" or "Dietary Mineral Supplements", as the case may be, and iii ; drugs that A ; contain a plant, mineral or animal substance in respect of which therapeutic activity or disease prevention activity is claimed, including traditional herbal medicines, traditional Chinese medicines, ayurvedic East Indian ; medicines and traditional aboriginal North American ; medicines, and B ; the medical use of which is based solely on historical and ethnological evidence from references relating to a medical system other than one based on conventional scientific standards; and fabricating, packaging labelling, testing, distributing, and importing of antimicrobial agents. 2 ; This Division and Divisions 2 to 4 not apply to the affixing of a label to a previously labelled. Betapace AF Betaxolol HCl Benazepril 5mg - 30 tabs 20mg Benazepril Hctz 10Caduet 12.5mg - 30 tabs Benazepril Hctz 2012.5mg - 30 tabs Calan Benazepril Hctz 20-25mg - 30 tabs Calan SR Benazepril Hctz 5-6.25mg Capoten - 30 tabs and co-trimoxazole.
Computed Tomography CT ; Scans 1. All scans of the brain, neck, chest, abdomen, and pelvis potentially involve the administration of intravenous contrast. Patients scheduled for these studies should: a. Drink at least 40 oz. of water throughout the day before the exam. b. Do not eat anything for 4 hours prior to the exam. c. Take usual medications with small sips of water. 2. CT scans of the extremities, joints, and spine generally do not require the administration of intravenous contrast, and do not require any special preparation. 3. Patients scheduled for CT of the chest should bring their most current chest X-ray with them. 4. CT Scans of the abdomen, pelvis, or lumbar spine may have to be postponed if there is excessive residual barium in the bowel from a recent X-ray examination. Nuclear Medicine Scans 1. Myocardial Perfusion Imaging NPO after midnight prior to the scan. Bring comfortable shoes, if scheduled for a treadmill stress test. Take normal medications EXCEPT: blood pressure medicines; which should be held for 12 hours prior to the exam. No caffeine for 24 hours prior to the appointment time. This includes decaffeinated soft drinks, coffee, and tea. ; 2. Hepatobiliary scans NPO 4-6 hours prior to exam. 3. All Bone scans and Renal scans Hydrate well 40 oz. of water ; 2-3 hours prior to exam. MRI Scans 1. Please refer to the Alliance MRI Patient Screening form. 2. Call our office at 919 ; 653-0380 with any questions related to the screening form. 3. All MRI patients will receive a call from our office 2 days prior to appointment for additional screening. CADUET LIPID DRUGS CHOLESTYRAMINE COLESTID ANTARA GEMFIBROZIL TABS tricor PREVALITE QUESTRAN WELCHOL TABS LOPID TABS LOFIBRA Use PA Form # 20420 Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug s ; exists. Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug s ; exists and benadryl and caduet.

Northern Blot Analysis. RNAs from several human tissues were extracted as described previously 18 ; . Total RNA was extracted by the method of Chomczynski and Sacci 19 ; and poly A ; + RNA isolated using oligo dT ; cellulose spin columns Pharmacia, Uppsala, Sweden ; . RNA was denatured and size fractionated on a 1% formaldehyde agarose gel, transferred onto nylon membrane and immobilized by UV irradiation. The blots were hybridized with a [32P]-labeled DNA fragment encoding the CysLT2 receptor, washed with 2X SSPE and 0.1% SDS at room temperature for 15 min and again with 0.5X SSPE and 0.1% SDS at 50oC for 45 min and four final washings with 0.2 X SSPE and 0.1% SDS at 50oC each for 1 hour and exposed to X-ray film at -70oC in the presence of an intensifying screen for 3-7 days. In situ Hybridization Analysis and Immunohistochemistry. The oligonucleotide antisense probes used for the in situ studies were: 5'-CCAGGCACTCCTGATGCT-3' 5'CCCACCACCAAGGAATA-3' and their complementary sequences were used as sense probes. Tailing of oligonucleotides with biotin-16-dUTP Boehringer Roche Mannheim ; was carried out as described by the manufacturer except for substitution of digoxigenindUTP with biotin-16-dUTP in the tailing reaction. In situ hybridization was carried out on 6 m cryostat sections of surgical human lung specimens National Disease Research Interchange, Philadelphia, PA ; using 2 pmol ml of labeled oligonucleotides for 18 h at 37C. Bound probe was visualized using Texas Red Tyramide Signal Amplification detection reagent NEN Life Sciences ; according to the manufacturer's instructions. Peripheral blood mononuclear cells PBMC ; were isolated from buffy coat preparations by centrifugation over lymphocyte separation medium LSM; ICN ; . T cells were rosetted by incubation of the PBMC with neuraminidase-treated sheep red blood cells SRBC ; and.

Elan Pharmaceuticals, Inc. formerly Athena Neurosciences, Inc. ; Director Feb. 1999 May 2002 ; , Associate Director Apr. 1997 Feb. 1999 ; , Manager Oct. 1995 Mar. 1997 ; Responsible for defining regulatory strategy for biologic and drug products in international development and commercialization. Represented Regulatory Affairs on development and commercialization teams. Primary regulatory contact to FDA CBER, CDER, and DDMAC ; and TPD as well as international corporate partners Canada, Germany, Japan, Switzerland, UK, and US ; . Supervised staff of six to support five marketed products, five US INDs for drug products, one US IND for a therapeutic vaccine, and five Canadian INDs. Represented Regulatory Affairs on the clearance committee to review and approve promotional materials. Established regulatory standards for promotional material, communicated them to marketing colleagues, and ensured compliance. Provided regulatory intelligence to colleagues and trained regulatory staff on regulatory intelligence activities. Participated in due diligence of two products that were successfully in-licensed Mysoline and Frova ; . Collaborated with European colleagues on international product development, regulatory strategy, and regulatory submissions. Accomplishments included: o Filing INDs in the US and Canada for a therapeutic monoclonal antibody Tysabri ; and a US IND for a therapeutic vaccine for Alzheimer's disease AN-1792 ; . o Negotiated approval of an NDA and an NDS for an orphan drug product Diastat ; and negotiated NDA approval of an anti-epilepsy drug Zonegran ; . Cygnus, Inc., Manager Aug. 1994 Oct. 1995 ; Responsible for all regulatory activity for five investigational transdermal products. Coordinated all planning for an NDA. Supported an on-site manufacturing facility by providing detailed review and approval of SOPs, analytical specifications, stability protocols, and master records. Supervised a staff of two. Collaborated with Analytical colleagues to define a comprehensive format for stability reports. Monitored Federal Register and FDA guidances, evaluated their impact on the company, and communicated assessment to colleagues. Represented Regulatory Affairs in re-engineering the drug development process at Cygnus. The Du Pont Merck Pharmaceutical Co., Manager 1992 1994 ; , Senior Regulatory Associate 1991 1992 ; Responsible for all US regulatory activity for two experimental anti-cancer drugs, including all FDA negotiations. Coordinated all planning for the preparation and submission of marketing applications in Europe, Canada, and the US. Monitored Federal Register and FDA guidances, evaluated their impact on the company, and communicated assessment to colleagues. A Likert scale questionnaire. They documented significant percentage reductions in symptoms after ESS, with excellent results in terms of nasal obstruction, headache, and postnasal drip. However, minor symptoms, such as cough, dental pain, and otalgia, were not evaluated. Similarly, information regarding the net positive response for many symptoms after ESS can be extracted from analysis of the quality-of-life literature in patients with CRS. In general, the literature supports reductions in major symptoms of CRS after ESS. These data clearly indicate that, from a symptom standpoint, ESS is effective at reducing most of the symptoms accompanying CRS. For comparison and discussion, the influence of surgery on symptom scores is related to effect size. The effect size is an excellent way to measure response for symptom scores, because it takes into account the overall pooled standard deviation, thereby standardizing the response variable into an interpretable coefficient. As noted, effect sizes greater than 0.8 may be considered quite good, thus indicating a substantial response to the intervention ie, ESS ; . In general, the effect size is much more meaningful from a clinical standpoint than the raw change in symptom score. We found that for the major symptoms of CRS, ESS provided effective relief, with the exception of hyposmia. Interestingly, ESS was beneficial in terms of effect sizes in reducing the minor symptoms of CRS, but the noted response was less in magnitude. Although headache is considered a minor symptom of CRS, it did respond well to ESS, with a large effect size. I was somewhat surprised at the response of systemic symptoms fever and fatigue ; to ESS. This response to ESS argues that CRS does, indeed, symptomatically affect more than just the head and neck regions, perhaps relating to the global quality-of-life effects of CRS. One drawback to the present study is the lack of a control group not undergoing ESS. There is a known placebo effect to surgical intervention, and this may in part account for some of the symptom responses.20 However, the effect sizes noted for major symptoms are substantially greater than would be expected by chance alone. Furthermore, extensive medical treatment has previously failed in these patients and, therefore, the patients are starting with a refractory state of health. Thus, there exists a selection bias for more difficult to treat cases that would tend to further emphasize the strength of the benefit realized from surgery. In addition, a previous investigation21 has shown that at least the radiographic com ARCHOTO, because side effect.

A24 MOLECULAR EPIDEMIOLOGY OF HEPATITIS C AMONG DRUG USERS : CORRELATION WITH CLINICAL PARAMETERS, SEXUAL BEHAVIOUR AND DRUG-RELATED RISK BEHAVIOUR. C. Mathe 1 ; , G. Robaeys 2 ; , M. Van Ranst 1 ; , P. Van Damme 3 ; , F. Buntinx 1 ; . 1 ; Katholieke Universiteit Leuven ; 2 ; Ziekenhuis Oost Limburg ; 3 ; Universiteit Antwerpen. Background : The Hepatitis C virus HCV ; is a single stranded RNA virus exhibiting an important genetic diversity. Determining the genotype is crucial for epidemiological as well as for clinical analysis since HCV genotypes differ according to the route of transmission, in geographic distribution and in response to treatment. The objective of this study was to determine the genotypic variation among drug users in 2 regions in Flanders and to relate the genotype distribution to the characteristics of the population. Methods : HCV-RNA quantification and genotyping was performed on samples from 161 anti-HCV positive drug users. A standardized interview providing information on their socio-demographic status, drug-related and sexual risk behaviour was available for each drug user. Results : HCV-RNA was present in 152 out of 161 samples. The genotype could be determined for 148 cases. Genotype 1 was predominant 48.6 % ; , followed by genotype 3 41.2 % ; , genotype 4 8.8 % ; and genotype 2 1.4 % ; . In the univariate analysis HCV genotype was related to geographic region, history of IDU, number of sexual partners last year, having a tattoo and the presence of anti-HBc. In the multivatiate analysis having no history of injecting drug use IDU ; was confirmed as a statistically significant predictor for an infection with genotype 1. Predictors for an infection with genotype 3 were found to be the presence of anti-HBc antibodies and a history of injecting drug use. Being tattooed emerged as a statistically significant pedictor for an infection with genotype 4. Conclusion : The distribution of HCV genotypes in IDU differs significantly from the distribution among non-IDU, genotype 3 being predominant among the former and genotype 1 among the latter. The results of this study are suggestive for a possible role of tattooing practices in the spread of HCV among drug users and ascorbic.